What question did this study set out to answer?

This study aims to develop antibodies that can cross the blood-brain barrier (BBB) effectively across multiple species.

CD98hc-targeted antibody shuttles for central nervous system delivery with broad cross-species reactivity

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial investigates CD98hc-targeted antibodies for CNS delivery, suggesting improved therapeutic applications.

This study aims to develop antibodies that can cross the blood-brain barrier (BBB) effectively across multiple species.
Utilized active learning to isolate anti-CD98hc antibodies.
Employed iterative mutagenesis and library optimization for antibody evolution.
Assessed binding affinities and brain delivery efficiency in mouse, cynomolgus monkey, and human models.
Developed a series of antibodies that show similar affinities for mouse, cyno, and human CD98hc.
Demonstrated efficient and long-lived delivery of antibodies across the BBB.
Eliminated the need for transgenic animals in preclinical testing.

WU et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark